Truist notes that Argenx (ARGX) announced the discontinuation of the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous in adults with moderate to severe thyroid eye disease, which the firm sees leaving more room for Viridian Therapeutics (VRDN) in that area and more market share up for grabs for both veligrotug and VRDN-003 SC in these patients. The firm keeps a Buy rating and $41 price target on Viridian shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics rises 5.0%
- Viridian Therapeutics: Positioned for Growth with Promising Pipeline and Strong Financials
- Viridian Therapeutics initiated with an Outperform at William Blair
- Viridian Therapeutics initiated with a Buy at Truist
- Promising Developments and Market Potential Drive Buy Rating for Viridian Therapeutics